{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:58:49Z","timestamp":1791899929220,"version":"4.3.4"},"reference-count":86,"publisher":"Xia & He Publishing","issue":"2","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.xiahepublishing.com"],"crossmark-restriction":false},"short-container-title":["J Clin Transl Hepatol"],"published-print":{"date-parts":[[2022,4,28]]},"DOI":"10.14218\/jcth.2021.00408","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T05:59:52Z","timestamp":1634882392000},"page":"374-382","update-policy":"https:\/\/doi.org\/10.14218\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science"],"prefix":"10.14218","volume":"10","author":[{"given":"Yasser","family":"Fouad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Regev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajarshi","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Torstenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Younes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet S.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Juergen","family":"Gruss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Y.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Bollipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Freilich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Gish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Schuppan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5334","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"key20211022055947_JCTH-D-21-00408-b2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tips.2019.05.002","article-title":"Genetic insights for drug development in NAFLD","volume":"40","author":"Eslam","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"key20211022055947_JCTH-D-21-00408-b3","first-page":"S0016-5085(20)30680-30686","article-title":"Why do so many NASH trials fail?","author":"Ratziu","year":"2020","journal-title":"Gastroenterology"},{"issue":"7","key":"key20211022055947_JCTH-D-21-00408-b4","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"issue":"10","key":"key20211022055947_JCTH-D-21-00408-b6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","article-title":"Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"key20211022055947_JCTH-D-21-00408-b7","first-page":"161","article-title":"Looking for a new name for non-alcoholic fatty liver disease in Spanish: esteatosis hep\u00e1tica metab\u00f3lica (EHmet)","volume":"113","author":"Romero-G\u00f3mez","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"issue":"3","key":"key20211022055947_JCTH-D-21-00408-b8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S2468-1253(21)00002-9","article-title":"Endorsing the redefinition of fatty liver disease","volume":"6","author":"Tan","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","article-title":"The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease","volume":"6","author":"Mendez-Sanchez","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"key20211022055947_JCTH-D-21-00408-b10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2468-1253(20)30213-2","article-title":"Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S2468-1253(20)30294-6","article-title":"Redefining fatty liver disease: an international patient perspective","volume":"6","author":"Shiha","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"key20211022055947_JCTH-D-21-00408-b13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/liv.14478","article-title":"What\u2019s in a name? Renaming \u2018NAFLD\u2019 to \u2018MAFLD\u2019","volume":"40","author":"Fouad","year":"2020","journal-title":"Liver Int"},{"issue":"5","key":"key20211022055947_JCTH-D-21-00408-b14","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jhep.2021.01.015","article-title":"The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD","volume":"74","author":"Spearman","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"key20211022055947_JCTH-D-21-00408-b15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/liv.14788","article-title":"From NAFLD to MAFLD: Nurse and allied health perspective","volume":"41","author":"Clayton","year":"2021","journal-title":"Liver Int"},{"issue":"2","key":"key20211022055947_JCTH-D-21-00408-b16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","article-title":"The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease","volume":"75","author":"Nan","year":"2021","journal-title":"J Hepatol"},{"issue":"9","key":"key20211022055947_JCTH-D-21-00408-b17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2468-1253(21)00132-1","article-title":"Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases","volume":"6","author":"Eslam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"key20211022055947_JCTH-D-21-00408-b18","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: A nationwide cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20211022055947_JCTH-D-21-00408-b19","doi-asserted-by":"crossref","first-page":"154433","DOI":"10.1016\/j.metabol.2020.154433","article-title":"MAFLD and risk of CKD","volume":"115","author":"Sun","year":"2021","journal-title":"Metabolism"},{"issue":"12","key":"key20211022055947_JCTH-D-21-00408-b20","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/liv.14675","article-title":"MAFLD identifies patients with significant hepatic fibrosis better than NAFLD","volume":"40","author":"Yamamura","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1740774514558307","article-title":"Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials","volume":"12","author":"Carlisle","year":"2015","journal-title":"Clin Trials"},{"key":"key20211022055947_JCTH-D-21-00408-b22","unstructured":"The liver line. Available from: https:\/\/liverline.com\/"},{"issue":"12","key":"key20211022055947_JCTH-D-21-00408-b23","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1007\/s11606-019-05340-9","article-title":"Low Awareness of nonalcoholic fatty liver disease in a population-based cohort sample: the CARDIA study","volume":"34","author":"Cleveland","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"4","key":"key20211022055947_JCTH-D-21-00408-b24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s10620-019-05700-9","article-title":"Awareness of nonalcoholic fatty liver disease is increasing but remains very low in a representative US cohort","volume":"65","author":"Singh","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"3","key":"key20211022055947_JCTH-D-21-00408-b25","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10620-018-5389-5","article-title":"Awareness and knowledge of nonalcoholic fatty liver disease among office employees in Beijing, China","volume":"64","author":"Zhang","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b26","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/MCG.0000000000000075","article-title":"Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk","volume":"49","author":"Wieland","year":"2015","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"key20211022055947_JCTH-D-21-00408-b27","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.jhep.2021.01.022","article-title":"Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback","volume":"74","author":"Alem","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"key20211022055947_JCTH-D-21-00408-b28","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/hep.26031","article-title":"Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition?","volume":"56","author":"Wattacheril","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b29","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"issue":"676","key":"key20211022055947_JCTH-D-21-00408-b30","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.3399\/bjgp18X699377","article-title":"GPs\u2019 experiences and perceptions of early detection of liver disease: a qualitative study in primary care","volume":"68","author":"Standing","year":"2018","journal-title":"Br J Gen Pract"},{"issue":"6","key":"key20211022055947_JCTH-D-21-00408-b31","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"6","key":"key20211022055947_JCTH-D-21-00408-b32","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/1756283X15611581","article-title":"Practice patterns in NAFLD and NASH: real life differs from published guidelines","volume":"9","author":"Rinella","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"issue":"6","key":"key20211022055947_JCTH-D-21-00408-b34","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1080\/00365521.2020.1766554","article-title":"Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)","volume":"55","author":"Gerhardt","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"5","key":"key20211022055947_JCTH-D-21-00408-b35","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2020.12.035","article-title":"Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists","volume":"74","author":"Fouad","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"key20211022055947_JCTH-D-21-00408-b36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2018","journal-title":"Hepatology"},{"issue":"S1","key":"key20211022055947_JCTH-D-21-00408-b37","first-page":"1287A","article-title":"Low eligibility for phase 3 clinical trials in a real-life cohort with nonalcoholic steatohepatitis","volume":"68","author":"Do","year":"2018","journal-title":"Hepatology"},{"issue":"10215","key":"key20211022055947_JCTH-D-21-00408-b38","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"9972","key":"key20211022055947_JCTH-D-21-00408-b39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"key20211022055947_JCTH-D-21-00408-b40","article-title":"FDA regulatory considerations for NASH clinical trial endpoints. FDA 2018","author":"Omokero"},{"issue":"3","key":"key20211022055947_JCTH-D-21-00408-b41","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/hep.30163","article-title":"ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis","volume":"69","author":"Daniels","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"key20211022055947_JCTH-D-21-00408-b42","doi-asserted-by":"crossref","first-page":"984","DOI":"10.14309\/ajg.0000000000001059","article-title":"A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients","volume":"116","author":"Eslam","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b43","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"key20211022055947_JCTH-D-21-00408-b44","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: A multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"key20211022055947_JCTH-D-21-00408-b45","doi-asserted-by":"crossref","first-page":"G807","DOI":"10.1152\/ajpgi.00447.2014","article-title":"Novel insights into the function and dynamics of extracellular matrix in liver fibrosis","volume":"308","author":"Karsdal","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"key20211022055947_JCTH-D-21-00408-b46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.addr.2017.07.014","article-title":"The good and the bad collagens of fibrosis - Their role in signaling and organ function","volume":"121","author":"Karsdal","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"key20211022055947_JCTH-D-21-00408-b47","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen","year":"2013","journal-title":"Am J Transl Res"},{"issue":"8","key":"key20211022055947_JCTH-D-21-00408-b48","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/apt.15427","article-title":"Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program","volume":"50","author":"Huber","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"10126","key":"key20211022055947_JCTH-D-21-00408-b49","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"issue":"11-12","key":"key20211022055947_JCTH-D-21-00408-b50","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/apt.13819","article-title":"Fibrosis is not just fibrosis - basement membrane modelling and collagen metabolism differs between hepatitis B- and C-induced injury","volume":"44","author":"Nielsen","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"key20211022055947_JCTH-D-21-00408-b51","first-page":"236","article-title":"Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C. J Viral Hepat","volume":"28","author":"Laursen","year":"2021"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12931-019-1118-7","article-title":"Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort","volume":"20","author":"Organ","year":"2019","journal-title":"Respir Res"},{"issue":"11","key":"key20211022055947_JCTH-D-21-00408-b53","doi-asserted-by":"crossref","first-page":"e0208136","DOI":"10.1371\/journal.pone.0208136","article-title":"Effects of emergency cerclage on the neonatal outcomes of preterm twin pregnancies compared to preterm singleton pregnancies: A neonatal focus","volume":"13","author":"Chun","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"key20211022055947_JCTH-D-21-00408-b54","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.2337\/dc18-2599","article-title":"Markers of collagen formation and degradation reflect renal function and predict adverse outcomes in patients with type 1 diabetes","volume":"42","author":"Pilemann-Lyberg","year":"2019","journal-title":"Diabetes Care"},{"key":"key20211022055947_JCTH-D-21-00408-b55","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5840\/philtopics20002816","article-title":"Shifting sands: An interest-relative theory of vagueness","volume":"28","author":"Graff","year":"2000","journal-title":"Philosophical topics"},{"issue":"2","key":"key20211022055947_JCTH-D-21-00408-b56","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cct.2013.05.009","article-title":"Clinical trials in the Middle East and North Africa (MENA) Region: grandstanding or grandeur?","volume":"36","author":"Nair","year":"2013","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b57","first-page":"10","article-title":"Future Prescriber","volume":"14","author":"IMS Institute global use of medicines: outlook through 2016"},{"issue":"8","key":"key20211022055947_JCTH-D-21-00408-b58","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"issue":"4","key":"key20211022055947_JCTH-D-21-00408-b59","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/liv.12100","article-title":"Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways","volume":"33","author":"Skoien","year":"2013","journal-title":"Liver Int"},{"issue":"5","key":"key20211022055947_JCTH-D-21-00408-b60","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b61","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","article-title":"Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis","volume":"156","author":"Loomba","year":"2019","journal-title":"Gastroenterology"},{"issue":"5","key":"key20211022055947_JCTH-D-21-00408-b62","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"key20211022055947_JCTH-D-21-00408-b63","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/flgastro-2017-100865","article-title":"Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent","volume":"9","author":"De Silva","year":"2018","journal-title":"Frontline Gastroenterol"},{"key":"key20211022055947_JCTH-D-21-00408-b64","doi-asserted-by":"crossref","DOI":"10.1111\/hepr.13685","article-title":"MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: Generalized estimating equation approach","author":"Tsutsumi","year":"2021","journal-title":"Hepatol Res"},{"issue":"4","key":"key20211022055947_JCTH-D-21-00408-b65","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jhep.2020.10.019","article-title":"Insights into contribution of genetic variants towards the susceptibility of MAFLD revealed by the NMR-based lipoprotein profiling","volume":"74","author":"Xia","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"key20211022055947_JCTH-D-21-00408-b66","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jhep.2020.07.008","article-title":"Letter regarding \u201cA new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement\u201d","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"key":"key20211022055947_JCTH-D-21-00408-b67","article-title":"Clinical validity of the diagnostic criteria for metabolic-associated fatty liver disease: a real-world experience","author":"Fouad","year":"2020","journal-title":"medRxiv"},{"issue":"S1","key":"key20211022055947_JCTH-D-21-00408-b68","first-page":"44","article-title":"Metabolic-associated fatty liver disease increases fbrosis severity in patients with chronic hepatitis C. J Gastroenterol Hepatol","volume":"35","author":"Al Omary","year":"2020"},{"issue":"3","key":"key20211022055947_JCTH-D-21-00408-b69","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/0956462420960997","article-title":"Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people","volume":"32","author":"Jongraksak","year":"2021","journal-title":"Int J STD AIDS"},{"issue":"4","key":"key20211022055947_JCTH-D-21-00408-b70","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/liv.14767","article-title":"Metabolic-associated fatty liver disease (MAFLD) in coeliac disease","volume":"41","author":"Rispo","year":"2021","journal-title":"Liver Int"},{"issue":"12","key":"key20211022055947_JCTH-D-21-00408-b71","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/liv.14640","article-title":"Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease","volume":"40","author":"Nascimbeni","year":"2020","journal-title":"Liver Int"},{"key":"key20211022055947_JCTH-D-21-00408-b72","first-page":"S1590-8658(20)31092-6","article-title":"Clinical characteristics of metabolic associated fatty liver disease (MAFLD) in subjects with myotonic dystrophy type 1 (DM1)","author":"Miele","year":"2021","journal-title":"Dig Liver Dis"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jhep.2021.04.021","article-title":"Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience","volume":"75","author":"M\u00e9ndez-S\u00e1nchez","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b74","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"key20211022055947_JCTH-D-21-00408-b76","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cld.2004.04.010","article-title":"Nonalcoholic fatty liver disease in the pediatric population","volume":"8","author":"Lavine","year":"2004","journal-title":"Clin Liver Dis"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b77","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MPG.0b013e31826d3c62","article-title":"Childhood obesity for pediatric gastroenterologists","volume":"56","author":"Huang","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"key20211022055947_JCTH-D-21-00408-b78","doi-asserted-by":"crossref","first-page":"e0140908","DOI":"10.1371\/journal.pone.0140908","article-title":"The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis","volume":"10","author":"Anderson","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"key20211022055947_JCTH-D-21-00408-b79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrgastro.2016.160","article-title":"Developmental origins of NAFLD: a womb with a clue","volume":"14","author":"Wesolowski","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"key20211022055947_JCTH-D-21-00408-b80","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"key20211022055947_JCTH-D-21-00408-b81","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.tig.2020.03.003","article-title":"The epigenetic drug discovery landscape for metabolic-associated fatty liver disease","volume":"36","author":"Bayoumi","year":"2020","journal-title":"Trends Genet"},{"issue":"2","key":"key20211022055947_JCTH-D-21-00408-b82","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and epigenetics of NAFLD and NASH: Clinical impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"key20211022055947_JCTH-D-21-00408-b83","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3390\/jcm8060868","article-title":"A systematic review of NAFLD-associated extrahepatic disorders in youths","volume":"8","author":"Pacifico","year":"2019","journal-title":"J Clin Med"},{"key":"key20211022055947_JCTH-D-21-00408-b84","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jpeds.2020.03.038","article-title":"Glomerular hyperfiltration is associated with liver disease severity in children with nonalcoholic fatty liver disease","volume":"222","author":"Yodoshi","year":"2020","journal-title":"J Pediatr"},{"issue":"4","key":"key20211022055947_JCTH-D-21-00408-b85","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jhep.2020.12.032","article-title":"NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change","volume":"74","author":"Hegarty","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"key20211022055947_JCTH-D-21-00408-b86","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/liv.14739","article-title":"The NAFLD-MAFLD debate: Eminence vs evidence","volume":"41","author":"Fouad","year":"2021","journal-title":"Liver Int"}],"container-title":["Journal of Clinical and Translational Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2021-00408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T18:20:12Z","timestamp":1783707612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2021-00408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":86,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,3,2]]},"published-print":{"date-parts":[[2022,4,28]]}},"alternative-id":["10.14218\/JCTH.2021.00408"],"URL":"https:\/\/doi.org\/10.14218\/jcth.2021.00408","relation":{},"ISSN":["2225-0719","2310-8819"],"issn-type":[{"value":"2225-0719","type":"print"},{"value":"2310-8819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}